ASKA: Sales Down 8.4% Due to Rebound from a Spike at Last Fiscal Year End

ASKA Pharmaceutical posted consolidated sales of ¥19,990 million, down 8.4% compared to the corresponding period of the previous year, due to a rebound from a spike following the Great East Japan Earthquake at the end of the previous fiscal year...read more